


GRANTED**(IN380783)**

Spectrophotometric real time method for assessment of fibrinolytic activity



NEED

Fibrinolytic agents play a crucial role in breaking down blood clots. But how can we accurately measure their effectiveness in real time? A new method promises simplicity and precision.

TECHNOLOGY OVERVIEW

This spectrophotometric method quantifies fibrin clot formation and fibrinolytic activity in real-time, enabling accurate assessment of fibrinolytic agents. It is cost-effective, highly sensitive, and reproducible, providing a reliable tool for blood clotting and thrombolysis research.

TECHNOLOGY KEY FEATURES

- 1) Real-time fibrinolytic activity monitoring.
- 2) Simple, cost-effective spectrophotometric assay.
- 3) High sensitivity and reproducibility.
- 4) Suitable for assessing a range of fibrinolytic agents.
- 5) Enables graphical analysis of fibrin clot dissolution.

[Read more here](#)

MARKET ANALYSIS

The global hemostasis and thrombosis diagnostics market is expected to grow at a CAGR of 6.5%, reaching \$20 billion by 2033. The demand for more accurate and cost-effective diagnostic tools is driving market growth. (Source: Markets and Markets, 2023)

Target Industries

- 1) Healthcare Diagnostics for blood clotting and thrombolysis monitoring.
- 2) Pharmaceuticals for developing and testing fibrinolytic agents.
- 3) Biotechnology for research on clotting disorders and therapeutic interventions.

AT A GLANCE

- SDG 3 (Good Health and Well-being), SDG 9 (Industry, Innovation, and Infrastructure), SDG 12 (Responsible Consumption and Production)

Technology is available for licensing/ co-development.

Reach out to Prof. Deepak Chitkara, Coordinator, BITS Technology Enabling Centre,

BITS Pilani Contact Details: tec.bits@pilani.bits-pilani.ac.in, 91 1596-255913